Manufacturing

Articles

Kriya Therapeutics completes $100 Million Series B financing to advance its platform for designing, developing, and manufacturing gene therapies. 

Kriya Therapeutics to Advance Gene Therapies with $100 Million Financing 

BioNTech plans to expand its global footprint by establishing its regional headquarters for southeast Asia and a new mRNA manufacturing facility in Singapore. 

BioNTech to Establish Regional Headquarters and mRNA Manufacturing Facility in Singapore

The expanded agreement will include aseptic fill/finish services at its San Diego, CA facility.

Aji Bio-Pharma Expands Agreement with AstraZeneca to Include Drug Product Manufacturing

EMA has approved the manufacturing of drug product for BioNTech’s COVID-19 vaccine, BNT162b2, at BioNTech’s manufacturing site located in Marburg, Germany. 

EMA Approves BioNTech’s COVID-19 Vaccine Manufacturing Site

The companies will aim to establish clinical and commercial supply agreements for Plus Therapeutics’ RNL-liposome drug product at the appropriate stage of development. 

Piramal Pharma Solutions to Provide Intermediate Drug Product Services to Plus Therapeutics 

The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.

Quotient Sciences Acquires CDMO Arcinova

Emergent will use its CDMO services to manufacture drug product batches to support the increased supply of the therapeutic candidate in anticipation of a potential emergency use authorization in the first quarter of 2021.

Emergent and Humanigen Form CDMO Compact for COVID-19 Therapeutic Candidate 

The expansion will include new suites for the development and clinical manufacturing of drug product intermediates and drug products and cGMP suites for early-phase cGMP manufacture.

Lonza to Expand Particle Engineering and Drug Product Capabilities at its Oregon Site

Samsung will offer large-scale commercial manufacturing for drug substance and drug products to support AstraZeneca’s biologics therapeutics capabilities in the Asia-Pacific region.

AstraZeneca and Samsung Biologics to Enter into Long-Term Supply Agreement for Up to $545.6 Million

The companies will utilize Avid’s upstream and downstream process development and drug substance manufacturing services in conjunction with Argonaut’s parenteral drug product fill-finish services for the delivery of CGMP parenteral drug products for use in clinical studies.

Manufacturing, Drug Products